PMID- 27072238
OWN - NLM
STAT- MEDLINE
DCOM- 20161223
LR  - 20161230
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 12
IP  - 1
DP  - 2016 Jan-Mar
TI  - The combined effects of all-trans-retinoic acid and docosahexaenoic acid on the 
      induction of apoptosis in human breast cancer MCF-7 cells.
PG  - 204-8
LID - 10.4103/0973-1482.154071 [doi]
AB  - INTRODUCTION: Breast cancer is one of the most women's cancers in the worldwide. 
      In vivo and in vitro studies showed that all-trans-retinoic acid (ATRA) and 
      docosahexaenoic acid (DHA) can modulate differentiation and apoptosis in both 
      cancer and immune cells. Nuclear retinoic acid receptors (RARs) and retinoid X 
      receptors (RXRs) activation in the presence of their ligands, plays a critical 
      role in the proliferation, differentiation, and apoptosis of normal cells. AIM OF 
      STUDY: We hypothesized that ATRA and DHA, as ligands of RARs and RXRs 
      respectively, may have synergistic effects on the induction of apoptosis in MCF-7 
      human mammary carcinoma cell lines. MATERIALS AND METHODS: MCF-7 cells were 
      seeded in a 24-well plate at 3 x 105 cells per well. The cells were treated with 
      5 microM ATRA, 30 DHA, and various combinations of them over a 3-day trial. Apoptosis 
      was measured by Annexin V-FITC kit and flow cytometery. RESULTS: Our results 
      showed that the combination treatment of ATRA and DHA (5 microM and 30 microM and half 
      dose at 2.5 microM and 15 microM, respectively) in a dose-dependent manner induced 
      apoptosis rate in MCF-7 cells significantly more than single treatment of ATRA or 
      DHA, as compared to control group (P < 0.05). CONCLUSION: We conclude that the 
      combination of ATRA and DHA at the well-balanced proportion may be effective in 
      cancer cell apoptosis. Further studies provide details about the potential 
      synergistically effects of combination treatment of ATRA and DHA in growth 
      inhibition and differentiation of human mammary cancer cells.
FAU - Abdolahi, Mina
AU  - Abdolahi M
FAU - Shokri, Fazel
AU  - Shokri F
FAU - Hosseini, Mostafa
AU  - Hosseini M
FAU - Shadanian, Maryam
AU  - Shadanian M
FAU - Saboor-Yaraghi, Ali-Akbar
AU  - Saboor-Yaraghi AA
AD  - Department of Cellular and Molecular Nutrition, Faculty of Nutritional Sciences 
      and Dietetics; Food Microbiology Research Center, Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Receptors, Retinoic Acid)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Apoptosis/*drug effects
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Cell Differentiation/drug effects
MH  - Docosahexaenoic Acids/*administration & dosage
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Receptors, Retinoic Acid/metabolism
MH  - Tretinoin/*administration & dosage
EDAT- 2016/04/14 06:00
MHDA- 2016/12/24 06:00
CRDT- 2016/04/14 06:00
PHST- 2016/04/14 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/12/24 06:00 [medline]
AID - JCanResTher_2016_12_1_204_154071 [pii]
AID - 10.4103/0973-1482.154071 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2016 Jan-Mar;12(1):204-8. doi: 10.4103/0973-1482.154071.